Claims for Patent: 8,492,336

Summary for Patent: 8,492,336

Title:	Methods of treating neuropathic pain with an environ polypeptide
Abstract:	There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid sequence from position 27 to 139 of the sequence illustrated in FIG. 1, or a functional equivalent, derivative or bioprecursor thereof. The nucleic acid molecule encoding enovin can be used to transform a host cell, tissue or organism by including it in an appropriate vector. The host cell, tissue or organism and the vector also form part of the invention.
Inventor(s):	Masure; Stefano Leo Jozef (Brasschaat, BE)
Assignee:	Janssen Pharmaceutica N.V. (BE)
Application Number:	12/974,625
Patent Claims:	1. A method for treating neuropathic pain involving sensory neurons of the peripheral nervous system involving a GFR.alpha.-3 receptor in a subject comprising administering to the subject an effective amount of a human neurotrophic growth factor polypeptide comprising: (a) seven conserved cysteine residues at positions 16, 43, 47, 80, 81, 109, and 111 when numbered in accordance with SEQ ID NO: 3; (b) amino acid residues as follows: C at position 16, L at position 18, V at position 25, L at position 28, G at position 29, L at position 30, G at position 31, E at position 36, F at position 40, Rat position 41, F at position 42, C at position 43, G at position 45, C at position 47, C at position 80, C at position 81, R at position 82, P at position 83, F at position 91, D at position 93, S at position 105, A at position 106, C at position 109 and C at position 111, each when numbered in accordance with SEQ ID NO: 3; and (c) an LGLG repeat, an FRFC motif, a QPCCRP motif, and a SATACGC motif; wherein said neurotrophic growth factor polypeptide is at least 90% homologous to the amino acid sequence of SEQ ID NO: 3; and wherein said neurotrophic growth factor polypeptide exerts its effect by binding to GFR.alpha.-3 receptor, thereby treating neurotrophic pain involving the GFR.alpha.-3 receptor of the sensory neurons of the peripheral nervous system. 2. The method according to claim 1, wherein the neurotrophic growth factor polypeptide comprises the amino acid sequence of SEQ ID NO: 3. 3. The method of claim 1, wherein said neurotrophic growth factor polypeptide is administered by a route selected from the group consisting of intravenous, subcutaneous, intramuscular, transdermal, and intracerebral. 4. The method of claim 1, wherein said neurotrophic growth factor polypeptide further comprises a pharmaceutically acceptable carrier. 5. The method of claim 4, wherein said pharmaceutically acceptable carrier is selected from the group consisting of saline, non-toxic-salt, and sterile water. 6. The method of claim 4, wherein said neurotrophic growth factor polypeptide is lyophilized and stored in sterile conditions prior to reconstitution by the addition of sterile water for subsequent administration. 7. The method of claim 1, wherein said neurotrophic pain results from exposure to neurotoxins. 8. The method of claim 1, wherein said neurotrophic pain results from peripheral nerve trauma. 9. The method of claim 1, wherein said neurotrophic pain is associated with gastrointestinal hypersensitivity. 10. A method for treating peripheral neuropathy involving sensory neurons comprising administering to a subject in need thereof an effective amount of a human neurotrophic growth factor polypeptide comprising amino acid sequence of SEQ ID NO: 3, wherein said neurotrophic growth factor exerts its effects by binding to GFR.alpha.-3 receptor of the sensory neurons. 11. The method of claim 10, wherein the human neurotrophic growth factor polypeptide consists of the amino acid sequence of SEQ ID NO: 3. 12. The method of claim 10, wherein said neurotrophic growth factor polypeptide is administered by a route selected from the group consisting of intravenous, subcutaneous, intramuscular, transdermal, intrathecal, and intracerebral. 13. The method of claim 10, wherein staid neurotrophic growth factor polypeptide further comprises a pharmaceutically acceptable carrier. 14. The method of claim 13, wherein said pharmaceutically acceptable carrier is selected from the group consisting of saline, non-toxic salt, and sterile water. 15. The method of claim 13, wherein said neurotrophic growth factor polypeptide is lyophilized and stored in sterile conditions prior to reconstitution by the addition of sterile water for subsequent administration. 16. The method of claim 10, wherein said peripheral neuropathy results from exposure to neurotoxins.

Details for Patent 8,492,336

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2018-07-14